Leukemias | Clinical

FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS

April 19, 2021

The FDA has granted an orphan drug designation to CA-4948, a first-in-class, small-molecule inhibitor of IRAK4, for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Ruxolitinib Extends MF Survival, Improves Quality of Life

April 14, 2021

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the impact of ruxolitinib on MF and other issues facing the patient population.

GTB-3550 Shows Early Efficacy as MDS and AML Therapy

April 13, 2021

GTB-3550 TriKE had demonstrated early clinical promise as a monotherapy for the treatment of high-risk myelodysplastic syndromes and refractory/relapsed acute myeloid leukemia.

sBLA Filed With FDA for Brexucabtagene Autoleucel in Adult ALL

April 02, 2021

A supplemental biologics license application for brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursors acute lymphoblastic leukemia.

Blinatumomab Improves Survival Outcomes Over Chemotherapy in High-Risk B-ALL

March 03, 2021

Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.

Gergis Explains the Differences Between Acute and Chronic GVHD

February 16, 2021

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each

Targeted Delivery of Iomab-B to the Marrow in Patients with R/R AML

February 16, 2021

Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.

FDA Grants 2 Breakthrough Therapy Designations to Asciminib in Ph+ CML

February 08, 2021

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Younger Patients, Select Subsets in AML May Have Higher Chances of Long-Term Survival

January 09, 2021

Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.

Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome

January 02, 2021

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.